Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 2
1997 6
1998 11
1999 11
2000 13
2001 20
2002 31
2003 52
2004 35
2005 51
2006 32
2007 48
2008 49
2009 53
2010 44
2011 49
2012 45
2013 60
2014 59
2015 58
2016 53
2017 37
2018 52
2019 57
2020 68
2021 77
2022 67
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,055 results
Results by year
Filters applied: . Clear all
Page 1
Gastrointestinal complications after kidney transplantation.
Gioco R, Corona D, Ekser B, Puzzo L, Inserra G, Pinto F, Schipa C, Privitera F, Veroux P, Veroux M. Gioco R, et al. World J Gastroenterol. 2020 Oct 14;26(38):5797-5811. doi: 10.3748/wjg.v26.i38.5797. World J Gastroenterol. 2020. PMID: 33132635 Free PMC article. Review.
Gastrointestinal complications are common after renal transplantation, and they have a wide clinical spectrum, varying from diarrhoea to post-transplant inflammatory bowel disease (IBD). Chronic immunosuppression may increase the risk of post-transplant infection
Gastrointestinal complications are common after renal transplantation, and they have a wide clinical spectrum, varying from diarrhoea to pos …
Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia.
Bradbury CA, Pell J, Hill Q, Bagot C, Cooper N, Ingram J, Breheny K, Kandiyali R, Rayment R, Evans G, Talks K, Thomas I, Greenwood R. Bradbury CA, et al. N Engl J Med. 2021 Sep 2;385(10):885-895. doi: 10.1056/NEJMoa2100596. N Engl J Med. 2021. PMID: 34469646 Clinical Trial.
BACKGROUND: Immune thrombocytopenia is a rare autoimmune disorder with associated bleeding risk and fatigue. ...CONCLUSIONS: The addition of mycophenolate mofetil to a glucocorticoid for first-line treatment of immune thrombocytopenia resulted i …
BACKGROUND: Immune thrombocytopenia is a rare autoimmune disorder with associated bleeding risk and fatigue. ...CONCLUSIONS: T …
The association of mycophenolate mofetil and human herpes virus infection.
Yun JSW, Yap T, Martyres R, Kern JS, Varigos G, Scardamaglia L. Yun JSW, et al. J Dermatolog Treat. 2020 Feb;31(1):46-55. doi: 10.1080/09546634.2019.1572864. Epub 2019 Oct 17. J Dermatolog Treat. 2020. PMID: 30676825 Review.
Purpose: Mycophenolate mofetil (MMF) is a steroid-sparing immunosuppressant used extensively to treat both common and rare dermatological conditions. ...This review presents current evidence regarding increased risk of human herpesvirus infection
Purpose: Mycophenolate mofetil (MMF) is a steroid-sparing immunosuppressant used extensively to treat both common and r …
Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF. Tunnicliffe DJ, et al. Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4. Cochrane Database Syst Rev. 2018. PMID: 29957821 Free PMC article. Review.
The following questions relating to management of proliferative lupus nephritis were addressed: 1) Are new immunosuppressive agents superior to or as effective as cyclophosphamide plus corticosteroids? 2) Which agents, dosages, routes of administration and du …
The following questions relating to management of proliferative lupus nephritis were addressed: 1) Are new immunosuppressive agent
Interventions for focal segmental glomerulosclerosis in adults.
Hodson EM, Sinha A, Cooper TE. Hodson EM, et al. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3. Cochrane Database Syst Rev. 2022. PMID: 35224732 Review.
Studies comparing different types, routes, frequencies, and duration of immunosuppressive agents and non-immunosuppressive agents were assessed. ...Five studies (240 participants) compared cyclosporin with or without prednisone with different comparato …
Studies comparing different types, routes, frequencies, and duration of immunosuppressive agents and non-immunosuppressive
SARS-CoV2 and immunosuppression: A double-edged sword.
Lai Q, Spoletini G, Bianco G, Graceffa D, Agnes S, Rossi M, Lerut J. Lai Q, et al. Transpl Infect Dis. 2020 Dec;22(6):e13404. doi: 10.1111/tid.13404. Epub 2020 Jul 17. Transpl Infect Dis. 2020. PMID: 32639598 Free PMC article. Review.
We conducted a literature review related to the impact of immunosuppression on coronavirus infections including case reports and series describing immunosuppression management in transplant recipients. The role of steroids, calcineurin inhibitors, and myco
We conducted a literature review related to the impact of immunosuppression on coronavirus infections including case reports a …
Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.
Danza A, Ruiz-Irastorza G. Danza A, et al. Lupus. 2013 Oct;22(12):1286-94. doi: 10.1177/0961203313493032. Lupus. 2013. PMID: 24098001 Review.
The impaired cellular and humoral immune functions seen in patients with SLE are predisposing conditions, whilst disease activity, prednisone doses over 7.5-10 mg/day, high doses of methylprednisolone or cyclophosphamide are well-recognised risk factors for infec
The impaired cellular and humoral immune functions seen in patients with SLE are predisposing conditions, whilst disease activity, pr …
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients t …
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kid …
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.
Colmenero J, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, Nuño J, Gastaca M, Bustamante-Schneider J, Cachero A, Lladó L, Caballero A, Fernández-Yunquera A, Loinaz C, Fernández I, Fondevila C, Navasa M, Iñarrairaegui M, Castells L, Pascual S, Ramírez P, Vinaixa C, González-Dieguez ML, González-Grande R, Hierro L, Nogueras F, Otero A, Álamo JM, Blanco-Fernández G, Fábrega E, García-Pajares F, Montero JL, Tomé S, De la Rosa G, Pons JA. Colmenero J, et al. J Hepatol. 2021 Jan;74(1):148-155. doi: 10.1016/j.jhep.2020.07.040. Epub 2020 Aug 1. J Hepatol. 2021. PMID: 32750442 Free PMC article.
Overall, 35 patients (31.5%) met criteria of severe COVID-19. Baseline immunosuppression containing mycophenolate was an independent predictor of severe COVID-19 (relative risk = 3.94; 95% CI 1.59-9.74; p = 0.003), particularly at doses higher than 1,000 mg/d …
Overall, 35 patients (31.5%) met criteria of severe COVID-19. Baseline immunosuppression containing mycophenolate was an indep …
Immunosuppressive agents for treating IgA nephropathy.
Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, Samuels JA, Molony DA, Schena FP, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2020 Mar 12;3(3):CD003965. doi: 10.1002/14651858.CD003965.pub3. Cochrane Database Syst Rev. 2020. PMID: 32162319 Free PMC article.
SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi-RCTs of treatment for IgA nephropathy in adults and children and that compared immunosuppressive agents with placebo, no treatment, or other immunosuppressive or non-immunosuppre
SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi-RCTs of treatment for IgA nephropathy in adults and children a …
1,055 results